Chronic Idiopathic Urticaria

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moderate-to-Severe Asthma Management

Clinical Trials in IBD.

A Review of the Critical Role of Imaging in Primary Liver Malignancy

Why Gene Therapy for Hemophilia?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Unraveling Clinical Developments in NASH

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Pseudomonas Lung Infections in Cystic Fibrosis

Progression After Cancer Immunotherapy in Advanced NSCLC

Understanding the Many Faces of Pseudobulbar Affect

Ask the Onychomycosis Expert, Part 1

New Standards of Care in ALK-Translocated Advanced NSCLC

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Advances in Dry Eye.

Chronic Idiopathic Urticaria:

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Multidisciplinary Perspectives on Interstitial Lung Diseases

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

Therapeutic Approaches to the Management of EDS in OSA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Perspectives on the Impact of Inflammation in OA

Battling Constipation

New Recommendations on How to Stage Hidradenitis Suppurativa

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

When to Start and What to Use

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Advances in Severe Asthma Management

Guide to Atopic Dermatitis

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

Optimizing Joint Health in Hemophilia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Challenges in LA SCCHN.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Foundations of Asthma.

Presentation transcript:

Chronic Idiopathic Urticaria

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US.

Introduction to Urticaria

Patient Case: Jayne

Underlying Causes of Urticaria

CIU

CIU and Angioedema

Laboratory Evaluation in Patients With CIU

Patient Case: Jayne (cont)

CIU Is a Life-Altering Condition

Assessing the Impact of CIU on Patients

Patient Case: Jayne (cont)

Step Care for CIU

Step Care for CIU (cont)

Dose Advancement of Second-Generation Antihistamines

Recommendations for Jayne

Patient Case: Jayne (cont)

Step Care for CIU (cont)

Step Care for CIU (cont)

Randomized Clinical Trials Support the Use of Omalizumab for CIU

Therapeutic Role for Anti-IgE Treatment

Selection of Alternative Agents

Jayne: Case Conclusion and Long-Term Management

Concluding Remarks

Abbreviations